Inebilizumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Generalized Myasthenia Gravis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Systemic Lupus Erythematosus · Phase 2

Also approved (7)
US
  • adult patients with immunoglobulin G4-Related Disease (IgG4-RD)FDA label
  • UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.FDA label
Product first approved 2020Outside this platform's coverage
EU
  • add-on to standard therapy for adults with generalised myasthenia gravis who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positiveamgen.com
  • adults with active immunoglobulin G4-related disease (IgG4-RD)Outside this platform's coverageamgen.com
  • Monotherapy for adults with AQP4-IgG seropositive neuromyelitis optica spectrum disorders (Uplizna)Outside this platform's coverageEMA
Product first approved 2022
CN
  • AQP4-antibody positive NMOSD in adults (Xinyue, Hansoh)
Product first approved 2022Outside this platform's coveragewww1.hkexnews.hk
JP
  • Prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica)
Product first approved 2021Outside this platform's coverageeyewire.news

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Other / comorbidity
NCT07598825 · Amgen
2026-12-18 – 2034-02-11 · Autoimmune Hepatitis, AIH
What this study did
NCT07851220 · Amgen
2026-10-01 – 2033-09-26 · Glomerulonephritis, Membranous
What this study did
NCT04540497 · Amgen
2020-12-04 – 2028-10-31 · IgG4 Related Disease
What this study did
NCT07132398 · Tianjin Medical University General Hospital
2025-09-01 – 2028-08-31 · Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD)
What this study did
NCT05198557 · Tanabe Pharma Corporation
2022-07-20 – 2026-08 · Systemic Sclerosis
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT02200770 · MedImmune LLC
2015-04-01 – 2020-11-06 · Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
What this study did
Phase 2 (10)
Generalized Myasthenia Gravis
NCT06987539 · Amgen
2026-07-21 – 2030-03-13 · Generalized Myasthenia Gravis
What this study did
Systemic Lupus Erythematosus
Other / comorbidity
NCT07222553 · Amgen
2026-10-21 – 2031-06-10 · Immunoglobulin G4-related Disease
What this study did
NCT07724834 · Charite University, Berlin, Germany
2026-12-01 – 2029-03-01 · Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
What this study did
NCT04372615 · University of Utah
2022-03-30 – 2028-09-30 · Autoimmune Encephalitis, Encephalitis
What this study did
NCT05549258 · Amgen
2023-07-03 – 2027-04-13 · Neuromyelitis Optica Spectrum Disorder
What this study did
NCT04174677 · Amgen
2019-12-27 – 2022-04 · Highly Sensitized Patients on Waiting List for Kidney Transplantation
What this study did
NCT03218163 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2017-09-27 – 2018-04-15 · Multiple Myeloma
What this study did
NCT01453205 · MedImmune LLC
2012-02-27 – 2016-07-11 · Diffuse Large B-Cell Lymphoma
What this study did
NCT01466153 · MedImmune LLC
2012-02-07 – 2016-01-08 · Chronic Lymphocytic Leukemia (CLL)
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT00983619 · MedImmune LLC
2010-04-16 – 2019-03-21 · B-cell Malignancies, Cancer
What this study did
NCT02271945 · MedImmune LLC
2014-12-01 – 2016-05-24 · Relapsed/Refractory Aggressive B-cell Lymphomas
What this study did
Phase 1 (4)
Other / comorbidity
NCT01861340 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2014-05 – 2016-07 · Myeloma
What this study did
NCT01585766 · MedImmune LLC
2012-04-24 – 2016-06-20 · Multiple Sclerosis, Relapsing Forms
What this study did
NCT01957579 · AstraZeneca
2011-05-25 – 2015-09-15 · Blood Cancer, Advanced B Cell Malignancies
What this study did
NCT00946699 · MedImmune LLC
2010-03 – 2014-03 · Scleroderma
What this study did
Phase 4 (4)
Other / comorbidity
NCT07010302 · Massachusetts General Hospital
2026-09-01 – 2030-05 · NMOSD
What this study did
NCT07862075 · Ruijin Hospital
2025-10-01 – 2028-09-30 · Type 1 AIP
What this study did
NCT06180278 · Amgen
2024-04-02 – 2028-06-26 · Neuromyelitis Optica Spectrum Disorder
What this study did
NCT06212245 · Hansoh BioMedical R&D Company
2024-02-25 – 2025-06-25 · Neuromyelitis Optica Spectrum Disorders
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07159893 · First Affiliated Hospital of Wenzhou Medical University
2025-09 – 2026-09 · Neuromyelitis Optica, Autoimmune Diseases, Demyelinating Autoimmune Diseases, CNS
What this study did

Competitive landscape

This mechanism is crowded: 18 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Generalized Myasthenia Gravis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Inebilizumab: this drugApprovedMonoclonal antibodyCD19Reliable signal
NCT04524273: Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population (Baseline and Week 26): Overall: Placebo -2.2 Score on a scale (95% CI -3 to -1.5) | Overall: Inebilizumab 300 mg -4.2 Score on a scale (95% CI -4.9 to -3.4)
Eculizumab (Soliris)ApprovedMonoclonal antibodyComplement C5Partial signal
NCT01997229: Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) missed
Efgartigimod Alfa (Vyvgart)ApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
Efgartigimod Alfa And Hyaluronidase (Vyvgart Hytrulo)ApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
Obecabtagene Autoleucel (Aucatzyl)
Approved(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
Tafasitamab
Approved(overall)
Monoclonal antibodyCD19
Reliable signal(overall)
No reviewed efficacy summary in this indication
CemdisiranPhase 3RNA / oligonucleotideComplement C5not yet gradedNo reviewed efficacy summary in this indication
Gefurulimab (Klygefa)Phase 3Antibody-derived scaffoldComplement C5not yet gradedNo reviewed efficacy summary in this indication
Iptacopan (Fabhalta)Phase 3Small moleculeComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
Pozelimab (Veopoz)Phase 3Monoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
Cemacabtagene Ansegedleucel
Phase 2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Rapcabtagene Autoleucel
Phase 2(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
AritinerceptPhase 1/2Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-619
—(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
GLPG5101
Discontinued
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Inebilizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
Phase 2Neuromyelitis Optica Spectrum DisorderRecruiting
Est. primary completion 2027-04-13 · NCT05549258 · CT.gov ↗
What to watch
August 2027 (1)
Phase 3Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD)Not yet recruiting
Est. primary completion 2027-08-31 · NCT07132398 · CT.gov ↗
What to watch
2028 (4)
June 2028 (1)
Phase 4Neuromyelitis Optica Spectrum DisorderActive not recruiting
Est. primary completion 2028-06-26 · NCT06180278 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Systemic Lupus ErythematosusRecruiting
Est. primary completion 2028-08-06 · NCT06570798 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2Autoimmune Encephalitis, EncephalitisRecruiting
Est. primary completion 2028-09-30 · NCT04372615 · CT.gov ↗
What to watch
Phase 4Type 1 AIPRecruiting
Est. primary completion 2028-09-30 · NCT07862075 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Phase 2Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID) …Not yet recruiting
Est. primary completion 2029-02-01 · NCT07724834 · CT.gov ↗
What to watch
2030 (2)
January 2030 (1)
Phase 4NMOSDRecruiting
Est. primary completion 2030-01 · NCT07010302 · CT.gov ↗
What to watch
March 2030 (1)
Phase 2Generalized Myasthenia GravisRecruiting
Est. primary completion 2030-03-13 · NCT06987539 · CT.gov ↗
What to watch
2031 (3)
June 2031 (1)
Phase 2Immunoglobulin G4-related DiseaseRecruiting
Est. primary completion 2031-06-10 · NCT07222553 · CT.gov ↗
What to watch
July 2031 (1)
Phase 3Autoimmune Hepatitis, AIHRecruiting
Est. primary completion 2031-07-30 · NCT07598825 · CT.gov ↗
What to watch
September 2031 (1)
Phase 3Glomerulonephritis, MembranousRecruiting
Est. primary completion 2031-09-27 · NCT07851220 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 February 2026ApprovalEuropean Commission approves UPLIZNA for generalized myasthenia gravis
EU, EC · Source ↗
11 December 2025ApprovalFDA approves UPLIZNA for generalized myasthenia gravis
US, FDA · Amgen · Source ↗
3 April 2025ApprovalFDA approves UPLIZNA for IgG4-RD
US, FDA · Source ↗
15 October 2024Topline resultMINT Phase 3 primary results
Amgen · Source ↗
5 June 2024Topline resultMITIGATE (NCT04540497) Phase 3 met its primary endpoint
Amgen · Source ↗